Miikana Therapeutics Inc.
This article was originally published in Start Up
Miikana Therapeutics Inc. is focused on in-licensing late-stage oncology compounds that fit well with the staff's expertise in cancer pathways effecting apoptosis and mitotic catastrophe. Longer term, it will discover and develop drugs internally against novel but validated targets such as kinases, and histone deacetylases.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.